Foundation of Guerbet
Guerbet was founded in 1926 by Marcel Guerbet in France, initially focusing on the production of x-ray contrast agents. This marked the beginning of a long-standing commitment to innovation in medical imaging.
1926
1930
Launch of First Contrast Agent
Guerbet introduced its first contrast agent, which was used for radiological examinations, setting a standard for quality and safety in medical imaging.
1960
Expansion into International Markets
Guerbet began its international expansion, establishing a presence in various countries to distribute its contrast agents, thereby increasing its global footprint in the medical imaging sector.
1970
Introduction of New Technologies
Guerbet invested in research and development, leading to the introduction of new technologies in contrast media, enhancing the safety and effectiveness of imaging procedures.
1992
Acquisition of Iodine-Based Contrast Agents
Guerbet acquired the rights to several iodine-based contrast agents, expanding its product portfolio and solidifying its position in the market.
1998
Launch of Gadovist®
Guerbet launched Gadovist®, a gadolinium-based contrast agent for MRI, which became a key product in its imaging portfolio, known for its high safety profile and effectiveness.
2000
Establishment of Guerbet Research Institute
Guerbet established the Guerbet Research Institute to foster innovation and research in the field of medical imaging, focusing on developing new contrast agents and technologies.
2005
Acquisition of the Contrast Agent Division of Mallinckrodt
Guerbet acquired the contrast agent division of Mallinckrodt, significantly enhancing its product offerings and market presence in North America.
2010
Launch of Contrast Agents for Interventional Imaging
Guerbet expanded its product line to include contrast agents specifically designed for interventional imaging, addressing the growing needs of healthcare professionals in this area.
2014
Acquisition of the German Company, Bracco Imaging S.p.A.'s Products
Guerbet acquired specific product lines from Bracco Imaging, further strengthening its position in the global market for contrast agents.
2018
Introduction of the New Digital Solutions Platform
Guerbet launched a new digital solutions platform aimed at enhancing the workflow of medical imaging departments, integrating advanced technologies for better patient management.
2020
Focus on Sustainability Initiatives
Guerbet implemented sustainability initiatives aimed at reducing the environmental impact of its operations and products, aligning with global health and environmental standards.
2022
Launch of New MRI Contrast Agent, Elucirem®
Guerbet launched Elucirem®, a new MRI contrast agent that offers improved imaging quality and safety, reaffirming its commitment to innovation in contrast media.
2023
Expansion of Global Partnerships
Guerbet expanded its global partnerships with healthcare providers and technology companies to enhance the development and distribution of its imaging solutions.
2024
Continued Investment in R&D for Advanced Imaging Technologies
Guerbet announced increased investments in research and development to explore advanced imaging technologies, focusing on artificial intelligence and machine learning applications in radiology.
